Adjust Font Increase Font Decrease Font
  • Email
  • Print
  • RSS Feed

Media Releases

WASHINGTON, D.C. (February 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “PhRMA is currently reviewing the final regulation of the Physician Payments Sunshine Act and looks forward to seeing how CMS addressed key concerns that were previously raised. PhRMA remains committed to the principles of the Sunshine Act and continues to believe that careful implementation is essential to ensuring that Sunshine fulfills its objective of usable, transparent, and understandable sharing of information.” About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies...

Latest Releases

12/6/2012
Washington, D.C. (December 6, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today in response to the September 3, 2012 Indonesian Presidential Decree (76/2012) that grants compulsory licenses on nine innovative biopharmaceutical products:
12/3/2012
Washington, D.C. (December 3, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on the President’s Council of Advisors on Science and Technology (PCAST) report:
11/28/2012
Two New Reports Show Remarkable Progress in Treatment Options for HIV/AIDS
Washington, D.C. (November 28, 2012) — America’s biopharmaceutical research companies are currently developing 73 innovative medicines and vaccines to help the nearly 1.2 million Americans living with HIV infection today, according to a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) released today.
11/26/2012
The Washington Post story ‘Can Drug Research Still Be Trusted?’ presents a one-sided view of the critically important scientific endeavors that explore and ultimately discover and produce life-saving innovative medicines.
11/26/2012
PhRMA Chairman Lechleiter to Meet with Government and Health Leaders to Discuss Policies to Support an Ecosystem for Medical Innovation
Washington, DC/Beijing (November 26, 2012) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today launched its China PhRMA Days 2012 (November 26-30). As a part of this year’s activities, John C. Lechleiter, Ph. D., chairman of PhRMA, will be meeting with officials from the Chinese government and scientific community involved in innovation policy, including those involved in science education, clinical trial infrastructure, and regulation of medical products to discuss policies needed to support an ecosystem for medical innovation in China.
11/14/2012
Results from 17 states represent nearly $53 billion spent with broad network of large, small businesses
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released new data highlighting the biopharmaceutical industry’s vital role in contributing to the U.S. economy. The data represent approximately $53 billion across 17 states, spent with businesses that provide important services and supplies in support of the industry’s mission to bring new medicines to patients. The results provide data at the local level for a subset of biopharmaceutical companies, and offer an impression of the industry’s impact on communities across the country.